These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28314697)

  • 81. Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation.
    Borensztajn KS; Bijlsma MF; Groot AP; Brüggemann LW; Versteeg HH; Reitsma PH; Peppelenbosch MP; Spek CA
    Exp Cell Res; 2007 Jul; 313(12):2622-33. PubMed ID: 17531220
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
    Narita Y; Hamamura K; Kashiyama M; Utsumi S; Kakizoe Y; Kondo Y; Ishitsuka Y; Jono H; Irie T; Mukoyama M; Saito H; Kadowaki D; Hirata S; Kitamura K
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450643
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
    Al-Horani RA
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):525-533. PubMed ID: 32918208
    [TBL] [Abstract][Full Text] [Related]  

  • 84. An online dual-enzyme co-immobilized microreactor based on capillary electrophoresis for enzyme kinetics assays and screening of dual-target inhibitors against thrombin and factor Xa.
    Wu ZY; Zhang H; Yang YY; Yang FQ
    J Chromatogr A; 2020 May; 1619():460948. PubMed ID: 32059867
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Preparation of an anticoagulant polyethersulfone membrane by immobilizing FXa inhibitors with a polydopamine coating.
    Wang C; Jiang D; Ge H; Ning J; Li X; Liao M; Xiao X
    J Biomater Sci Polym Ed; 2024 Jul; ():1-15. PubMed ID: 39082937
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Factor Xa induces pro-inflammatory cytokine expression in RAW 264.7 macrophages via protease-activated receptor-2 activation.
    Zuo P; Zuo Z; Wang X; Chen L; Zheng Y; Ma G; Zhou Q
    Am J Transl Res; 2015; 7(11):2326-34. PubMed ID: 26807180
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A new WHO reference reagent for activated blood coagulation factor X (FXa), human (15/102).
    Thelwell C; Hogwood J; Daniels S; Rigsby P
    J Thromb Haemost; 2020 Jan; 18(1):255-257. PubMed ID: 31461800
    [No Abstract]   [Full Text] [Related]  

  • 88. Rivaroxaban Suppresses Atherosclerosis by Inhibiting FXa-Induced Macrophage M1 Polarization-Mediated Phenotypic Conversion of Vascular Smooth Muscle Cells.
    Ma Y; Zhang Y; Qiu C; He C; He T; Shi S; Liu Z
    Front Cardiovasc Med; 2021; 8():739212. PubMed ID: 34869643
    [No Abstract]   [Full Text] [Related]  

  • 89. Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
    Arce M; Pinto MP; Galleguillos M; Muñoz C; Lange S; Ramirez C; Erices R; Gonzalez P; Velasquez E; Tempio F; Lopez MN; Salazar-Onfray F; Cautivo K; Kalergis AM; Cruz S; Lladser Á; Lobos-González L; Valenzuela G; Olivares N; Sáez C; Koning T; Sánchez FA; Fuenzalida P; Godoy A; Contreras Orellana P; Leyton L; Lugano R; Dimberg A; Quest AFG; Owen GI
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31382462
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Alboserpin, the Main Salivary Anticoagulant from the Disease Vector
    Shrivastava G; Valenzuela-Leon PC; Chagas AC; Kern O; Botello K; Zhang Y; Martin-Martin I; Oliveira MB; Tirloni L; Calvo E
    Immunohorizons; 2022 Jun; 6(6):373-383. PubMed ID: 35738824
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Inhibitory Effect of Rivaroxaban on Atrial Arrhythmogenesis via Protease-Activated Receptor 2 Pathway.
    Kaikita K; Tsujita K
    Circ J; 2021 Jul; 85(8):1392-1393. PubMed ID: 33814527
    [No Abstract]   [Full Text] [Related]  

  • 92. Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose.
    Carr BM; Roy DJ; Bangh SA; Hellmich TR; Walker LE
    Clin Pract Cases Emerg Med; 2018 Aug; 2(3):247-250. PubMed ID: 30083644
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Letter by Borst Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1".
    Borst O
    Circ Res; 2020 Apr; 126(8):e53. PubMed ID: 32271683
    [No Abstract]   [Full Text] [Related]  

  • 94. Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".
    Violi F; Carnevale R; Pignatelli P; Cammisotto V
    Circ Res; 2020 May; 126(10):e114-e115. PubMed ID: 32379576
    [No Abstract]   [Full Text] [Related]  

  • 95. Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1".
    Petzold T; Thienel M; Dannenberg L; Mourikis P; Helten C; Ayhan A; M'Pembele R; Achilles A; Trojovky K; Zhang Z; Regenauer R; Pircher J; Ehrlich A; Lüsebrink E; Nicolai L; Stocker TJ; Brandl R; Röschenthaler F; Strecker J; Saleh I; Spannagl M; Mayr CH; Schiller HB; Jung C; Gerdes N; Hoffmann T; Levkau B; Hohlfeld T; Zeus T; Schulz C; Kelm M; Polzin A
    Circ Res; 2020 Apr; 126(8):e54-e55. PubMed ID: 32271680
    [No Abstract]   [Full Text] [Related]  

  • 96. Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".
    Petzold T; Dannenberg L; Thienel M; Ahlbrecht S; Mourikis P; Helten C; M'Pembele R; Achilles A; Zikeli D; Zhang Z; Lüsebrink E; Nicolai L; Saleh I; Jung C; Gerdes N; Hoffmann T; Levkau B; Hohlfeld T; Zeus T; Schulz C; Kelm M; Polzin A
    Circ Res; 2020 May; 126(10):e116-e117. PubMed ID: 32379578
    [No Abstract]   [Full Text] [Related]  

  • 97. Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X.
    Zhang ZL; Chen C; Qu SY; Ding Q; Xu Q
    Front Mol Biosci; 2022; 9():877170. PubMed ID: 35601826
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
    Steppich B; Dobler F; Brendel LC; Hessling G; Braun SL; Steinsiek AL; Deisenhofer I; Hyseni A; Roest M; Ott I
    J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004
    [TBL] [Abstract][Full Text] [Related]  

  • 99. After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding.
    Mehta SR
    Ann Intern Med; 2017 Mar; 166(6):JC29. PubMed ID: 28320003
    [No Abstract]   [Full Text] [Related]  

  • 100. Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban.
    Crowley MP; Cuadrado MJ; Hunt BJ
    Thromb Res; 2017 May; 153():37-39. PubMed ID: 28319823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.